Research programme: sustained-release tigecycline - Eagle Pharmaceuticals

Drug Profile

Research programme: sustained-release tigecycline - Eagle Pharmaceuticals

Alternative Names: Tigecycline extended-release - Eagle Pharmaceuticals; Tigecycline SR - Eagle Pharmaceuticals

Latest Information Update: 09 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eagle Pharmaceuticals
  • Class Antibacterials; Glycylcyclines; Small molecules
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Bacterial infections

Most Recent Events

  • 03 Jan 2017 Flamel Technologies completed its cross-border merger with Avadel Pharmaceuticals and is now called Avadel Pharmaceuticals
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Bacterial-infections in USA (SC, Controlled release)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top